Refer a Patient

If you have a patient with HR+/HER2- locally advanced or metastatic breast cancer whose tumor has a mutation in a gene called PIK3CA, they may be eligible to participate in the ReDiscover-2 Study.

Find a participating site

About the ReDiscover-2 Study

The ReDiscover-2 Study is evaluating an investigational study drug in participants living with locally advanced or metastatic breast cancer whose tumor has a mutation in the PIK3CA gene. The trial aims to learn more about the safety and effectiveness of the study drug in comparison to a standard approved treatment.

Study Purpose

The purpose of the ReDiscover-2 Study is to assess the efficacy and safety of zovegalisib (RLY-2608) + fulvestrant versus capivasertib + fulvestrant as treatment for PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Study Design

This is a Phase 3, open-label, randomized trial that is enrolling approximately 540 participants globally to receive either zovegalisib in combination with fulvestrant or capivasertib in combination with fulvestrant.

Patients who join the ReDiscover-2 Study will participate in the trial for several months or up to a year or longer. During that time, there will be a screening period, treatment period, and follow-up period. Participants will visit the study site approximately once per month during the treatment period.

For additional trial details, visit ClinicalTrials.gov.

About the Investigational Study Drug

The investigational study drug, zovegalisib, is an oral capsule taken twice daily. Capivasertib is an oral tablet taken twice daily for 4 days followed by 3 days off every week. Fulvestrant is administered at the study site as 2 injections given twice in the first cycle, then once per cycle thereafter.

Key Eligibility Criteria

To be considered for the trial, eligible participants must have:

  • HR+/HER2- advanced breast cancer
  • An eligible PIK3CA mutation with no known PTEN or AKT mutation
  • HbA1c < 7% and fasting plasma glucose < 140 mg/dL at baseline
  • Progression in metastatic or adjuvant setting on or after:
    • Only 1 prior CDK4/6 inhibitor, and
    • 1 or 2 prior endocrine therapies
  • No more than 1 prior line of chemotherapy
  • 6 months or longer duration of therapy on frontline ET regimen

Eligible participants must NOT:

  • Have metaplastic or inflammatory breast cancer
  • Have prior treatment with any of the following:
    • CDK2 inhibitors. Prior treatment with other investigational CDK inhibitors may be permitted upon discussion with and approval from the Sponsor
    • PI3K, AKT, or mTOR inhibitors, or any agent whose mechanism of action is to inhibit the PI3K/AKT/mTOR pathway
    • Immunotherapy
    • Antibody drug conjugates
  • Have known activating AKT mutations, loss-of-function PTEN mutations, or loss of PTEN expression resulting in oncogenic pathway activation downstream of PI3K

Refer a Patient

If you have a patient who may be interested in participating, and you think may qualify, refer your patient to this trial website.

Find a Site Near You

To learn more or refer a patient, please contact the Relay Therapeutics team. You can also view the full list of participating research sites or search by location to determine which site you are interested in referring a patient to.

Active site locations

Future site locations